ArticleAntibiotics (Basel, Switzerland)2021
Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Rifampin Based Therapy for Patients With Staphylococcus aureus Native Vertebral Osteomyelitis: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Pooled it
- Rifampicin in Osteoarticular Infections: A Comprehensive Review of Current Evidence.Antibiotics (Basel, Switzerland) · 2026Review
- Pathobiology of ESKAPE Biofilms in implant infections: current understanding and implications for future therapeutic strategies.Frontiers in cellular and infection microbiology · 2026Review
- Gentamicin fails to eradicateJournal of bone and joint infection · 2026Article
- Article
- Article
- Monitoring intracellular replication dynamics unveils high proportion of non-replicating antibiotic-tolerant Staphylococcus aureus inside osteoblasts.PLoS pathogens · 2025Article
- Combination Antibiotic Therapy for Orthopedic Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Enhanced Biofilm Disruption in Methicillin-ResistantPathogens (Basel, Switzerland) · 2025Article
- Targeting Chronic Biofilm Infections With Patient-derived Phages: An In Vitro and Ex Vivo Proof-of-concept Study in Patients With Left Ventricular Assist Devices.Open forum infectious diseases · 2025Article
- Antimicrobials in Orthopedic Infections: Overview of Clinical Perspective and Microbial Resistance.Medicina (Kaunas, Lithuania) · 2024Review
- Do High Doses of Multiple Antibiotics Loaded into Bone Cement Spacers Improve the Success Rate in Staphylococcal Periprosthetic Joint Infection When Rifampicin Cannot Be Employed?Antibiotics (Basel, Switzerland) · 2024Article
- Antibiotics with antibiofilm activity - rifampicin and beyond.Frontiers in microbiology · 2024Review
- Biofilm antimicrobial susceptibility testing: where are we and where could we be going?Clinical microbiology reviews · 2023Review
- Prevention of Ventriculostomy Related Infection: Effectiveness of Impregnated Biomaterial.International journal of molecular sciences · 2023Review
- Antimicrobial treatment of patients with a periprosthetic joint infection: basic principles.Arthroplasty (London, England) · 2023Review
- Article
- Extended local release and improved bacterial eradication by adding rifampicin to a biphasic ceramic carrier containing gentamicin or vancomycin.Bone & joint research · 2022Article
- Infectious Diseases Impact on Biomedical Devices and Materials.Biomedical materials & devices (New York, N.Y.) · 2022Review
- Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rifampin is a potent antibiotic against staphylococcal implant-associated infections. In the absence of implants, current data suggest against the use of rifampin combinations. In the past decades, abundant preclinical and clinical evidence has accumulated supporting its role in biofilm-related infections.In the present article, experimental data from animal models of foreign-body infections and clinical trials are reviewed. The risk for emergence of rifampin resistance and multiple drug interactions are emphasized. A recent randomized controlled trial (RCT) showing no beneficial effect of rifampin in patients with acute staphylococcal periprosthetic joint infection treated with prosthesis retention is critically reviewed and data interpreted. Given the existing strong evidence demonstrating the benefit of rifampin, the conduction of an adequately powered RCT with appropriate definitions and interventions would probably not comply with ethical standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.